ClinicalTrials.gg
Active, not recruitingNCT05926635Updated Sep 27, 2024

Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy

An observational study in Cerebral Palsy, sponsored by MarsiBionics. Active, not recruiting at 5 sites in Spain. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by MarsiBionics · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.

Planned enrollment
4th of 10
60 · median 50
Started
2023
with 9 others
Observational
10 of 54
2 open now
Primary completion
2025-05
later than 6 of 16 live
Registered
31st of 54
by date
Lead sponsor
8 of 54
MarsiBionics

Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 10 that started in 2023, is one of 10 observational ones, reaches primary completion later than 6 of the 16 other live ones, and was the 31st registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Cerebral Palsy with a site in Spain, or all of them as a file.
02

Study summary

Cerebral Palsy (CP) is the first cause of motor disability in children worldwide. ATLAS 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability. The objective of this study is to analyse the efficacy of a training program with ATLAS 2023 in chilren with CP.

Read the detailed description

A sample of children with CP will be divided into 2 groups, the experimental group will receive 32 sesions withe the ATLAS 2030 exoskeleton, whereas the control group will continue to receive their regular conventional therapy. Assessments will be performed at the beginning and the end of the intervention, as well as after 6, 9 and 12 months of the end of the intervention for follow-up.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • exoskeleton
  • cerebral palsy
  • gait
  • rehabilitation
04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children diagnosed with cerebral palsy with Gross Motor Function Classification level III (children walk using a hand-held mobility device in most indoor settings) or IV (children use methods of mobility that require physical assistance or powered mobility in most settings).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical authorization for standing, gait training and weight bearing.
  • signed by legal guardians.
  • Confirmed diagnosis of cerebral palsy GMFCS levels III or IV.
  • Proper family acceptance and commitment level.
  • Receiving a minimum of 2 hours of therapy/activities promoting physical activity.
  • Maximum user weight of 35 kg.
  • Hip width (between greater trochanteres) less than or equal to 35 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 24cm to 33cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23cm to 32cm.
  • Shoe size 27-33 (EU)

Exclusion criteria

Exclusion Criteria:

  • More than 8 sessions of robotic therapy during a month in the previous year to the beginning of the study.
  • Intensive rehabilitation during the study.
  • Imposibility of the family to fulfill treatment calendar.
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee flessum at the time of using the exoskeleton.
  • Necessity to walk with 10º of hip abduction.
  • Necessity to walk with more than 9º of ankle dorsiflexion or plantar flexion or impossibility to use an orthosis to reach 90º in the ankle joint.
  • Severe skin lesion on parts of the lower extremities that are in contact with the device.
  • Scheduled surgery (rachis, limbs) for the duration of the study or surgery performed (rachis, extremities) in the last 6 months.
  • History of fracture without trauma. History of bone fracture traumatic in lower extremities or pelvic girdle in the last 3 months.
  • Severe rigid orthopedic deformities of the spine and/or lower limbs.
  • Cognitive or conductual disorders that may lead to a lack of adherence to the attachment to the device.
  • Conditions that provoke exercise intolerance.
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness or the inability to understand simple comands.
  • Allergy to any of the ATLAS materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exoskeleton group

    sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their of their routine rehabilitation

    Device: ATLAS 2030

  • Control group

    The children included in the control group will continue receiving their usual conventional therapy

Interventions

  • DeviceATLAS 2030

    sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation

06

What researchers measure

Primary outcomes

  1. Gross Motor Function Measure-88 (GMFM-88)

    To measure changes in gross motor function in children with cerebral palsy using the Gross Motor Functional Measure-88. The minimum value is 0 and the maximum value is 100 .When the GMFM score is lower, the skill level is lower.

    Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)

Secondary outcomes

  1. Modified Ashworth Scale (MAS)

    changes in spasticity measured by the Modified Ashworth Scale (MAS). The spasticity of each muscle group is measured with a scale scored from 0 to 4, where 0 means no spasticity and 4 means the joint is fixed and therefore, the highest level of spasticity

    Time frame: Through study completion, along 1 year

  2. Pediatric Quality of Life Inventory (PedsQLTM)

    Changes in self perceived quality of life measured by the Pediatric Quality of Life Inventory (PedsQLTM). Every item is measured on a scale from 0 (higher quality of life) to 4 (lower quality of life)

    Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)

  3. Changes in Gait Deviation Index (GDI)

    Changes in Gait Deviation Index (GDI) measured with a tridimensional motion analysis system

    Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for May 2025, 21 months after the start.

Of 221 observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jul 3, 2023
StartActual
Aug 3, 2023
Primary completionEst.
May 11, 2025
CompletionEst.
May 11, 2025
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05926635
Lead sponsor
MarsiBionics
Collaborators
National Research Council, Spain, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Hospital Universitario La Paz, Hospital Universitario 12 de Octubre, Hospital General Universitario Gregorio Marañon
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Aug 3, 2023
Primary completion
May 11, 2025 (estimated)
Completion
May 11, 2025 (estimated)
Last update
Sep 27, 2024

Study contacts

Olga Arroyo Riaño
principal investigator · Hospital Universitario Gregorio Marañón
María Teresa Vara Arias
principal investigator · Hospital Infantil Universitario Niño Jesús
Ignacio Martínez Caballero
principal investigator · Hospital Infantil Universitario Niño Jesús
Sandra Espinosa García
principal investigator · Hospital Univsersitario La Paz
Sofía García de las Peñas
principal investigator · Hospital 12 de Octubre
Elena García Armada
principal investigator · National Research Council, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion